Skip to main content
Ferozsons Laboratories Limited logo

Ferozsons Laboratories Limited — Investor Relations & Filings

Ticker · FEROZ ISIN · PK0005201014 PSX Manufacturing
Open in API
Filings indexed 155 across all filing types
Latest filing 2025-04-29 Interim / Quarterly Rep…
Country PK Pakistan
Listing PSX FEROZ

About Ferozsons Laboratories Limited

https://ferozsons-labs.com/

Ferozsons Laboratories Limited is a pharmaceutical company engaged in the import, manufacturing, and sale of pharmaceutical products and medical devices. It is recognized as a leading provider of treatments, notably in Hepatology. The company maintains exclusive agreements with international partners for distribution, selling, and co-marketing. Its product portfolio encompasses Pharma & OTC products and Medical Technologies, serving patients and physicians, with an emphasis on exports.

Recent filings

Filing Released Lang Actions
Financial Results for the Quarter Ended 2025-03-31
Interim / Quarterly Report Classification · 100% confidence The document contains detailed financial statements including a Condensed Interim Unconsolidated Statement of Financial Position, Statement of Profit or Loss, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows. The financial data is for the nine months and quarter ended 31 March 2025, indicating it is a report for a period shorter than a full fiscal year. The presence of actual financial statements and substantive financial data confirms this is an interim or quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2025-04-29 English
Transmission of Quarterly Report for the Period Ended 2024-12-31
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Financial Information For The Half Year Ended 31 December 2024' and contains detailed financial statements including statements of financial position, profit or loss, comprehensive income, changes in equity, and cash flows for both standalone and consolidated entities. It also includes a Directors' Review Report and an Independent Auditor's Review Report. The content covers a six-month period ending 31 December 2024, which is a period shorter than a full fiscal year. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2025-02-28 English
Financial Results for the Quarter Ended 31-12-2024
Regulatory Filings
2025-02-28 English
Corporate Briefing Session - Presentation
Regulatory Filings
2024-11-26 English
Corporate Briefing Session
Regulatory Filings
2024-11-22 English
Transmission of Quarterly Report for the Period Ended 2024-09-30
Regulatory Filings
2024-10-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.